Imagine a battlefield medic or an ER surgeon stopping a massive hemorrhage in seconds—without clamps, pressure, or panic. That’s not science fiction; it’s the reality Cresilon is building with its plant-based hydrogel technology, backed by $111M in funding to date.

"Cresilon doesn't just stop bleeding—it eliminates the time-critical friction that costs lives in trauma and surgery."

The company, led by CEO Joe Landolina, is targeting a massive TAM in surgical and trauma care. The presence of keywords like 'Traumagel' alongside the main brand suggests they are capturing intent around specific product lines, while the high volume for 'cresilon inc medical devices 2026 cresilon summer biotechnology internship' signals a strong pull for top-tier talent—a crucial leading indicator for a deep-tech company.

• Differentiator: Plant-based composition (unlike chemical or animal-based alternatives).
• Speed: Hemostasis in seconds, reducing blood loss and OR time.
• Versatility: Effective across diverse wound types and geometries.
• No Prep: Eliminates the 'application lag' common in current hemostatic agents.